A study on the efficacy of preoperative marking for liver tumors difficult to identify intraoperatively

Ohdan Hideki0 个研究点目标入组 25 人开始时间: 2023年1月25日最近更新: 2023年11月20日

适应症

试验速览

暂无简介。

•1.Patients who are already scheduled for percutaneous biopsy or contrast-enhanced catheterization for diagnostic purposes of liver tumor or liver tissue.
•2.Patients scheduled for hepatic resection for liver tumor.
•3.Patients with Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-1.
•4.Male or female patients (regardless of outpatient or inpatient status) who are at least 18 years of age at the time of consent.
•5.Patients with clear tumor lesions in the liver on CT, MRI, or other imaging studies. The number of tumors is not specified.
•6.Patients with no intervening organs in the puncture pathway and who are considered to be able to be punctured safely under CT or ultrasound guidance.
•7.Patients who meet the following criteria in blood tests at the time of enrollment and whose major organs (bone marrow, liver, kidney, lungs, etc.) are still functional.
•A) White blood cell count: 2,000/mm3 or higher
•B) Hemoglobin level: 8.0 g/dL or higher
•C) Platelet count: 50,000/mm3 or higher
•D) Total bilirubin: 3.0 mg/dL or less
•8.Patients who have sufficient judgment to understand the content of the study and have given written consent to participate in this study.
•9.Patients who are able to take a break from anticoagulants on the day of marking.

•1.Patients with severe ischemic heart disease (NYHA classification III or higher).
•2.Patients with severe hepatic cirrhosis (hepatic impairment level C).
•3.Patients with dyspnea requiring oxygen administration due to interstitial pneumonia or pulmonary fibrosis.
•4.Patients on dialysis for chronic renal failure.
•5.Patients with active multiple cancers who are currently undergoing treatment.
•6.Patients with psychosis or psychiatric symptoms that make it difficult for them to participate in the study.
•7.Patients who are deemed inappropriate to participate in the study by the principal investigator or subinvestigator.
•8.Patients with hypersensitivity to platinum alloys.

发起方

Ohdan Hideki